X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (658) 658
Publication (118) 118
Government Document (11) 11
Book Chapter (9) 9
Dissertation (6) 6
Book Review (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
erbb3 (546) 546
humans (397) 397
index medicus (345) 345
oncology (250) 250
animals (226) 226
female (209) 209
receptor, erbb-3 - metabolism (181) 181
expression (151) 151
cell line, tumor (146) 146
cancer (145) 145
cell biology (140) 140
mice (129) 129
receptor, erbb-3 - genetics (129) 129
biochemistry & molecular biology (122) 122
her3 (122) 122
erbb2 (112) 112
breast cancer (107) 107
signal transduction (106) 106
male (98) 98
receptor, erbb-2 - metabolism (96) 96
phosphorylation (95) 95
article (91) 91
growth-factor receptor (91) 91
activation (90) 90
epidermal-growth-factor (90) 90
breast-cancer (87) 87
egfr (83) 83
heregulin (81) 81
skin and connective tissue diseases (80) 80
epidermal growth factor (76) 76
phosphatidylinositol 3-kinase (68) 68
proteins (68) 68
tumors (68) 68
apoptosis (65) 65
gene expression (65) 65
cell proliferation (64) 64
cells (64) 64
growth (64) 64
tyrosine kinase (64) 64
gene expression regulation, neoplastic (63) 63
receptor, epidermal growth factor - metabolism (62) 62
receptor, erbb-2 - genetics (60) 60
receptor, erbb-3 - antagonists & inhibitors (60) 60
receptor (58) 58
analysis (57) 57
breast neoplasms - pathology (57) 57
immunohistochemistry (57) 57
kinases (56) 56
middle aged (56) 56
breast neoplasms - metabolism (54) 54
resistance (53) 53
signal transduction - drug effects (53) 53
survival (53) 53
therapy (53) 53
research (52) 52
up-regulation (52) 52
proliferation (51) 51
tyrosine (51) 51
adult (50) 50
family (50) 50
neuregulin-1 - metabolism (49) 49
erbb4 (48) 48
aged (47) 47
proto-oncogene proteins c-akt - metabolism (47) 47
cell proliferation - drug effects (46) 46
protein (46) 46
trastuzumab (46) 46
breast neoplasms - genetics (45) 45
rats (45) 45
neuregulin (44) 44
breast neoplasms - drug therapy (43) 43
genetic aspects (43) 43
prognosis (43) 43
tumor cells, cultured (43) 43
antineoplastic agents - pharmacology (42) 42
down-regulation (42) 42
ligands (42) 42
metastasis (42) 42
overexpression (42) 42
genetics & heredity (41) 41
her2 (40) 40
mutation (40) 40
phosphatidylinositol 3-kinases - metabolism (39) 39
blotting, western (36) 36
quinazolines - pharmacology (36) 36
receptor, epidermal growth factor - genetics (36) 36
body regions (35) 35
egf receptor (35) 35
neoplasms (35) 35
xenograft model antitumor assays (35) 35
biology (34) 34
inhibition (34) 34
lung-cancer (34) 34
care and treatment (33) 33
medicine, research & experimental (33) 33
factor receptor (32) 32
receptor, erbb-4 (32) 32
monoclonal antibodies (31) 31
monoclonal-antibody (31) 31
protein binding (31) 31
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cellular Signalling, ISSN 0898-6568, 05/2012, Volume 24, Issue 5, pp. 1074 - 1085
EGFR family members are tyrosine kinase transmembrane receptors that, in response to specific extracellular ligands, activate cytoplasmic pathways involved in... 
Cyclind1 | Nuclear ErbB3 | Proliferation | P14ARF
Journal Article
The Oncologist, ISSN 1083-7159, 08/2019, Volume 24, Issue 8, pp. 1095 - 1102
Background Seribantumab (MM‐121) is a fully human IgG2 monoclonal antibody that binds to human epidermal growth factor receptor 3 (HER3/ErbB3) to block... 
Seribantumab | Antibody | Targeted therapy | Biomarkers | HER3/ErbB3 | Heregulin | Translational | ErbB3 | RECEPTOR | OVARIAN-CANCER | PLATINUM-RESISTANT | PACLITAXEL | CETUXIMAB | ONCOLOGY | PATRITUMAB | HER3
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 07/2019, Volume 25, Issue 19, pp. 5752 - 5758
ErbB3 and its ligand neuregulin-1 (NRG1) are widely expressed in head and neck squamous cell carcinoma (HNSCC) and associated with tumor progression. A... 
neuregulin | CDX-3379 | ErbB3, head and neck squamous cell carcinoma | HER3
Journal Article
Oncotarget, ISSN 1949-2553, 2015, Volume 6, Issue 28, pp. 24823 - 24841
Patients with metastatic melanoma bearing V600 mutations in BRAF oncogene clinically benefit from the treatment with BRAF inhibitors alone or in combination... 
Anti-ErbB3 antibodies | ErbB3 activation | In vivo regrowth impairment | BRAF/MEK inhibitors | Melanoma | SURVIVAL | in vivo regrowth impairment | MUTANT MELANOMA | ACQUIRED-RESISTANCE | melanoma | RECEPTOR | MEK INHIBITORS | FEEDBACK INHIBITION | CANCER | OVERCOME | CELL BIOLOGY | RAF | VEMURAFENIB | Receptor, ErbB-3 - metabolism | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Epitopes - immunology | Melanoma - genetics | Receptor, ErbB-3 - immunology | Indoles - pharmacology | Pyrimidinones - pharmacology | Phosphorylation - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Antibodies, Monoclonal - immunology | Proto-Oncogene Proteins B-raf - metabolism | Melanoma - metabolism | MAP Kinase Kinase 1 - antagonists & inhibitors | Antibodies, Monoclonal - pharmacology | Receptor, ErbB-3 - antagonists & inhibitors | MAP Kinase Kinase 1 - metabolism | Sulfonamides - pharmacology | Blotting, Western | Drug Synergism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Animals | Antibodies, Monoclonal - administration & dosage | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Cell Line, Tumor | Mice | Protein Kinase Inhibitors - pharmacology | Mutation | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Pyridones - pharmacology | Drug Resistance, Neoplasm - drug effects
Journal Article
Journal of Cellular Physiology, ISSN 0021-9541, 12/2018, Volume 233, Issue 12, pp. 9110 - 9120
Journal Article
Cellular Signalling, ISSN 0898-6568, 05/2012, Volume 24, Issue 5, pp. 1074 - 1085
EGFR family members are tyrosine kinase transmembrane receptors that, in response to specific extracellular ligands, activate cytoplasmic pathways involved in... 
Nuclear ErbB3 | Cyclind1 | Proliferation | p14ARF
Journal Article
Cancers, ISSN 2072-6694, 09/2019, Volume 11, Issue 10, p. 1425
In recent years the introduction of target therapies with BRAF and MEK inhibitors (MAPKi) and of immunotherapy with anti-CTLA-4 and anti-PD-1 monoclonal... 
neuregulin1 | melanoma | ErbB3 phosphorylation | adaptive resistance | CTCs | target therapy
Journal Article
Cancer, ISSN 0008-543X, 04/2018, Volume 124, Issue 7, pp. 1358 - 1373
BACKGROUND In contrast to lung cancer, few precision treatments are available for colorectal cancer (CRC). One rapidly emerging treatment target in CRC is... 
trastuzumab | microsatellite instability | tumor mutational burden | human epidermal growth factor receptor 2 (HER2) | lapatinib | comprehensive genomic profiling | pertuzumab | ERBB2, ERBB3 | colorectal adenocarcinoma | GENE-MUTATIONS | DOMAIN | PERTUZUMAB PLUS TRASTUZUMAB | PHASE-II | GROWTH-FACTOR RECEPTOR | LUNG-CANCER | ERBB3 | ONCOLOGY | ERBB2 | METASTATIC BREAST-CANCER | THERAPEUTIC TARGET | HIGH-FREQUENCY | GENOMIC ALTERATIONS | Microsatellite Instability | Prognosis | Follow-Up Studies | Receptor, ErbB-2 - genetics | Colorectal Neoplasms - genetics | Genomics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Male | Molecular Targeted Therapy | Young Adult | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Child | Receptor, ErbB-3 - genetics | Gene Amplification | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Aged | Biomarkers, Tumor - genetics | Mutation | Colorectal Neoplasms - pathology | TOR protein | Immunohistochemistry | Genes | Lung cancer | Colorectal carcinoma | Colorectal cancer | Clinical trials | Fluorescence | Microsatellite instability | Breast carcinoma | Alterations | Epidermal growth factor | Mismatch repair | Fluorescence in situ hybridization | Dimerization | Medical research | Microsatellites | Stability | ErbB protein | ErbB-3 protein | ErbB-2 protein | 1-Phosphatidylinositol 3-kinase | Amplification | Rectum | Cancer | Original
Journal Article
British Journal of Cancer, ISSN 0007-0920, 08/2011, Volume 105, Issue 4, pp. 523 - 533
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2012, Volume 366, Issue 2, pp. 109 - 119
Journal Article
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, ISSN 1756-9966, 08/2016, Volume 35
Background: The heregulin-1 beta/HER3-driven pathway is implicated in several epithelial malignancies and its blockade is currently undergoing clinical... 
CANCER PATIENTS | SURVIVAL | SENSITIVITY | KINASE INHIBITORS | HER3/ERBB3 | MESENCHYMAL TRANSITION | Liver cancer | GROWTH-FACTOR RECEPTOR | ERBB3 | ONCOLOGY | Hepatitis virus | PROTEIN EXPRESSION | DEGRADATION | Insulin receptor | HEPATOMA
Journal Article
MOLECULAR CANCER RESEARCH, ISSN 1541-7786, 04/2019, Volume 17, Issue 4, pp. 963 - 973
Uveal melanoma is the most common intraocular tumor in adults and often metastasizes to the liver, leaving patients with few options. Recurrent activating... 
BRAF GENE | ACTIVATION | COUNTER-CURRENT CHROMATOGRAPHY | ERBB3 | ONCOLOGY | HIPPO SIGNALING PATHWAY | LANDSCAPE | GNAQ | MUTATIONS | MEK INHIBITORS | G-PROTEIN | CELL BIOLOGY
Journal Article
International Journal of Cancer, ISSN 0020-7136, 10/2019, Volume 145, Issue 7, pp. 1838 - 1851
Journal Article